- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00885105
Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age
Evaluation of Serologic Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® Vaccine at 2 Months of Age
The study is to compare the 2 Groups with respect to antibody responses to inactivated influenza vaccine.
Observational Objectives:
- To describe the percentage of participants with protective Hemagglutinin (HAI) antibody titers to each of the 3 vaccine antigens in both study groups following each vaccination.
- To describe the HAI geometric mean titer (GMTs) to each of the 3 vaccine antigens in both study groups following each vaccination.
- To describe the safety of the 2005-2006 pediatric formulation of Fluzone® vaccine in both study groups.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
-
-
Georgia
-
Marietta, Georgia, Vereinigte Staaten, 30062
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27704
-
-
Ohio
-
Dayton, Ohio, Vereinigte Staaten, 45404
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15241
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98040
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participant is between 6 and 10 months of age on the day of inclusion (has reached 6-month but has not reached 11-month anniversary of birth).
- Available for the duration of the study.
- Born at full term of pregnancy (≥ 36 weeks) with a birth weight ≥ 2.5 kg
- Parent/legal acceptable representative willing and able to provide informed consent.
- Parent/legal acceptable representative able to attend all scheduled visits and comply with all trial procedures.
- Parent/legal acceptable representative willing to permit venipuncture for purposes of collecting a blood sample.
- Previously enrolled in the 2-month-old group in Study GRC27 or approved by sponsor for enrollment as control.
Exclusion Criteria:
- Reported allergy to egg proteins, chicken proteins, or any other constituent of Fluzone vacccine.
- Previous history of influenza vaccination (Group 2 subjects only).
- Receipt of any vaccine in the 14 days prior to enrollment.
- An acute illness with or without fever (rectal temperature ≥ 38.0 °C [or ≥100.4 °F]) in the 72 hours preceding enrollment in the trial.
- Known bleeding disorder.
- Participation in any other interventional (e.g., vaccine, drug) clinical trial (except Study GRC27) within 30 days prior to enrollment, or planned participation in another interventional clinical trial prior to termination of the subject's participation in this study.
- Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth.
- Personal or immediate family history of congenital immune deficiency.
- Developmental delay, neurologic disorder, or seizure disorder.
- Chronic medical, congenital or developmental disorder that could interfere with trial conduct or completion.
- Known human immunodeficiency virus (HIV)-positive or hepatitis B surface antigen (HBsAg)-positive mother.
- Known HIV, hepatitis B, or hepatitis C infection.
- Receipt of blood or blood-derived products within the past 2 months.
- Prior history of Guillain-Barré syndrome.
- Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Fluzone® Vaccine-Primed Group
Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)
|
0.25 mL, Intramuscular
Andere Namen:
|
Aktiver Komparator: Influenza Vaccine-Naive Group
Participants who have never received influenza vaccine (and not in Study GRC27)
|
0.25 mL, Intramuscular
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Summary of Influenza Seroprotection Post-vaccination With Fluzone® Vaccine.
Zeitfenster: Day 28 Post-vaccination
|
Seroprotection was defined as a Reciprocal Hemagglutination Inhibition Titers of ≥ 40 Post-vaccination with Fluzone® Vaccine.
|
Day 28 Post-vaccination
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Post-Vaccination With Fluzone® Vaccine.
Zeitfenster: Day 28 Post-vaccination
|
Antibodies against Influenza virus in Fluzone® Vaccine determined by the Hemagglutination inhibition (HAI) assay method.
|
Day 28 Post-vaccination
|
Geometric Mean Titers (GMTs) for Pertussis, Tetanus, Diphtheria, and Haemophilus Influenzae, Antigens Post-vaccination With Fluzone® Vaccine.
Zeitfenster: Day 28 Post-vaccination
|
Antibodies against Pertussis, Tetanus, and Haemophilus influenzae antigens were determined by an indirect Enzyme linked immunosorbent assay (ELISA). Anti-diphtheria antibody response was measured by the Vero Cells - diphtheria toxin challenge method. The serological determinations of total anti-PRP antibody was performed using a Farr-type radioimmunoassay. |
Day 28 Post-vaccination
|
Geometric Mean Titers (GMTs) for Polyribosylribitol Phosphate and Pneumococcal Antibodies After Concomitant Vaccination With Fluzone® Vaccine.
Zeitfenster: Day 28 post-vaccination
|
Human antibodies to Streptococcus pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) were determined by an Enzyme linked immunosorbent assay (ELISA).
|
Day 28 post-vaccination
|
Geometric Mean Titers (GMTs) for Polio Antibodies After Concomitant Vaccination With Fluzone® Vaccine.
Zeitfenster: Day 28 post-vaccination
|
Antibodies to polio viruses were measured by a serum neutralization assay.
|
Day 28 post-vaccination
|
Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-vaccination With Fluzone® Vaccine.
Zeitfenster: Days 0 up to 7 post-vaccination
|
Solicited injection site reactions: Tenderness, erythema and swelling.
Solicited systemic reactions: Fever (temperature), vomiting, abnormal crying, drowsiness, loss of appetite, and irritability.
|
Days 0 up to 7 post-vaccination
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- GRC32
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Influenza Virus Vaccine
-
Maisonneuve-Rosemont HospitalRekrutierung
-
State University of New York - Upstate Medical...Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research and...Aktiv, nicht rekrutierend
-
West China HospitalRekrutierungBösartiger TumorChina
-
U.S. Army Medical Research and Development CommandState University of New York - Upstate Medical UniversityAbgeschlossenDengueVereinigte Staaten
-
State University of New York - Upstate Medical...Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research and...Abgeschlossen
-
State University of New York - Upstate Medical...U.S. Army Medical Research and Development Command; Janssen Pharmaceutica N.V...Abgeschlossen
-
Hadassah Medical OrganizationZurückgezogenMetastasierender Krebs | Newcastle-Disease-Virus (NDV)Israel
-
CHU de ReimsAbgeschlossen
-
Uppsala UniversitySwedish University of Agricultural SciencesAbgeschlossenInfektionen der Atemwege | Respiratory-Syncytial-Virus-InfektionenSchweden
-
Oswaldo Cruz FoundationConselho Nacional de Desenvolvimento Científico e Tecnológico; Rio de Janeiro...UnbekanntMikrozephalie | Entwicklung des Kindes | ZIKA-VIRUS-INFEKTIONBrasilien